Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc.

Overview
Date Founded

2002

Headquarters

2200 PENNSYLVANIA AVENUE NW,, SUITE 300E, WASHINGTON, DC, 20037

Type of Company

Public

Employees (Worldwide)

270

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology

Company Description

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Contact Data
Trying to get in touch with decision makers at Vanda Pharmaceuticals Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Benefit Plan Administrator

Chief Marketing Officer

Senior Vice President & Chief Commercial Officer

Chief People Officer

Chief Corporate Affairs & Communications Officer

Senior Vice President, Business Development

Vice President-Manufacturing

Senior Vice President, General Counsel & Secretary

Co-Founder & Head, Business Development

Board of Directors

Director at Atterx BioTherapeutics

President & Chief Executive Officer at Vanda Pharmaceuticals Inc.

President & Chief Executive Officer at Aevi Genomic Medicine, Inc.

Chief Strategy Officer at Libra Group Ltd.

Former Partner at Ernst & Young LLP

Paths to Vanda Pharmaceuticals Inc.
Potential Connections via
Relationship Science
You
Vanda Pharmaceuticals Inc.
Owners & Shareholders
Details Hidden

Palo Alto Investors, LLC (PAI) is a leading private investment firm. We make long-term investments for high-net-worth and institutional investors based on original, deep, fundamental research. We don’t rent stocks. We own them. With approximately $900 million in assets under management, we offer a diversified micro cap fund and healthcare sector funds. Significant partner ownership in all of our Funds serves to align our financial interests with the financial interests of our clients. At PAI our mission is to deliver superior returns to our clients by investing for the long term. At the core of our investment philosophy lies the belief that intensive, original research is required to discover and evaluate inefficiently priced equities. We generally focus our investments in micro cap and small cap U.S. equities, which are not closely followed by Wall Street sell-side research firms. We target overlooked, misunderstood and undervalued segments of the equity markets, such as healthcare, energy and technology that have significant potential for appreciation. Our experienced research team has extensive industry experience in the sectors they cover. They utilize a disciplined, bottom-up approach to identify promising investments, and the firm’s investment policies ensure liquidity horizons that are sufficient to take advantage of new opportunities. PAI is committed to providing exemplary client service, maintaining the highest level of ethics, operational excellence and professionalism. PAI is independently owned, and has been registered with the SEC since its inception in 1989

Details Hidden

Consonance Capital Management's (CCM) funds seek to deliver exceptional, uncorrelated risk adjusted returns. CCM seeks to meet this objective by focusing on investment opportunities in the publicly traded stocks of healthcare companies. The firm invests in all sub-sectors of the healthcare sector including healthcare information technology, managed care, pharmaceuticals, specialty pharmaceuticals, commercial stage biotechnology, healthcare facilities and services, medical devices and supplies, diagnostics and consumer-based healthcare companies.CCM believes the public healthcare market lends itself to an active long/short strategy. The firm focuses on creating long and short portfolios driven by the opportunity for absolute return and alpha creation. The funds also invest in other types of securities and may use a variety of investment techniques to generate profit and/or control risk. These may include participating in swaps, buying or selling futures contracts, purchasing and writing options and other derivative contracts, purchasing or selling debt instruments, and trading on margin by borrowing funds and pledging securities as collateral. CCM invests primarily in healthcare companies in the US, and on an opportunistic basis in the rest of the world.^

Details Hidden

Armistice Capital LLC is a hedge fund manager located in New York City.

Recent Transactions
Details Hidden

Vanda Pharmaceuticals Inc. issued USD Common Stock

Details Hidden

Vanda Pharmaceuticals Inc. issued Common Stock

Details Hidden

Vanda Pharmaceuticals Inc. issued Common Stock

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Auditor

Advised onVanda Pharmaceuticals Inc. issued USD Common Stock

Escrow Agent

Advised onVanda Pharmaceuticals Inc. issued USD Common Stock

Legal Advisor

Advised onVanda Pharmaceuticals Inc. issued USD Common Stock

Legal Advisor

Advised onVanda Pharmaceuticals Inc. issued USD Common Stock

Managing Director

Advised onVanda Pharmaceuticals Inc. issued Common Stock

Professional

Advised onVanda Pharmaceuticals Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Paul, Weiss, Rifkind, Wharton & Garrison LLP

Publicist

Vice President at Makovsky & Co., Inc.

Clients

Probiomed SA de CV develops and manufactures pharmaceutical products. Develop high quality products to resolve health problems in an effective and economic way, from their capacity in biotechnology, with a high national integration and added value. PROBIOMED is a pioneering firm in Mexico that produces drugs through recombinant DNA technology, such as efficient way cancer, AIDS, hepatitis B and C, as well as organic insufficiencies such as kidney failure, to mention just a few. Its goal is to use its biotechnological capacity to develop products of the very highest quality so as to solve health problems in an efficient manner. Its biotechnological capacity is almost entirely domestic, since neither raw materials nor intermediate products are imported. The company was founded in 1970 and is headquartered in Mexico City, Mexico.

Key Stats and Financials As of 2018
Market Capitalization
$740M
Total Enterprise Value
$1.13B
Earnings Per Share
$0.48
Revenue
$193M
Net Profit
$25.2M
Total Equity
$275M
EBITDAMargin
12.79%
Enterprise Value Sales
5.84x
TEVNet Income
44.77x
Debt TEV
0x
EBITDA
$24.7M
Total Debt
$0
Enterprise Value EBITDAOperating
45.7x
Three Year Compounded Annual Growth Rate Of Revenue
20.66%
Five Year Compounded Annual Growth Rate Of Revenue
41.64%
Investors
Details Hidden

Partner at Care Capital LLC

Details Hidden

MedImmune Ventures invests in both public and private biotechnology companies located across the globe primarily in North America. The firm targets companies operating in the fields of molecules, vaccines, pharmaceutical technologies, medical devices, diagnostics, imaging and healthcare IT. The firm provides financing for seed, early, later and mezzanine stage capital requirements with an investment size ranging from $5 to $10 million per round.

Details Hidden

Domain Associates invests exclusively in emerging life sciences companies. The firm focuses on pharmaceuticals, specialty pharmaceuticals and medical devices and they are also interested in biomaterials, bioinstrumentation and diagnostics. They prefer to be part of the first institutional financing round of a company. They look for companies with outstanding technology addressing unmet needs in very large markets led by exceptional management. Once invested, Domain takes an active role in guiding the growth of the company. They take a seat on the Board of Directors in the vast majority of cases. Most of their investments are in private companies, but they also invest in small-cap public healthcare companies that are implementing a new corporate strategy.

Suppliers
Bristol-Myers Squibb Company Medical Support Services | New York, New York

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Novartis AG Hospitals & Patient Services | Basel, BS

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following four segments: Innovative Medicines, Alcon, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Eli Lilly & Company Hospitals & Patient Services | Indianapolis, Indiana

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. It operates through the following segments: Human Pharmaceutical Products and Animal Health Products. The Human Pharmaceutical products segment includes the discovery, development, manufacturing, marketing and sales of human pharmaceutical products worldwide in the following therapeutic areas: neuroscience, endocrinology, oncology, cardiovascular and other. The Animal health Products segment operating through the Elanco Animal Health division, develops, manufactures, and markets products for both food and companion animals. The Animal health products include Rumensin, Tylan, Posilac, Paylean and other products for livestock and poultry, as well as Trifexis, Comfortis, and other products for companion animals. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Pfizer, Inc. Pharmaceuticals - New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Vanda Pharmaceuticals Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Vanda Pharmaceuticals Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Vanda Pharmaceuticals Inc..